Invention Grant
- Patent Title: IP receptor agonist heterocyclic compounds
-
Application No.: US14767500Application Date: 2014-02-11
-
Publication No.: US09604981B2Publication Date: 2017-03-28
- Inventor: Rebecca Butler , Catherine Leblanc , Stephen Carl McKeown , Steven John Charlton
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agent Shawn Britt
- International Application: PCT/IB2014/058905 WO 20140211
- International Announcement: WO2014/125413 WO 20140821
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61K31/4375
Abstract:
The present invention provides heterocyclic derivatives of formula (Ia) which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.
Public/Granted literature
- US20150376183A1 IP Receptor Agonist Heterocyclic Compounds Public/Granted day:2015-12-31
Information query
